Valneva SE (VALN) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, Valneva SE's filing signal turned negative.

Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. The company employs a targeted approach, aiming for first-, best-, or only-in-class vaccine solutions across various modalities. Valneva currently markets three proprietary travel vaccines: IXIARO for Japanese encephalitis, DUKORAL for cholera and ETEC-related diarrhea, and IXCHIQ for chikungunya. Its pipeline includes VLA15, a Lyme disease vaccine candidate in Phase 3 development with Pfizer, and S4V2, a Shigella vaccine candidate in Phase 2 development with LimmaTech Biologics. The company operates manufacturing facilities in Scotland and Sweden, supported by a global commercial infrastructure.

Revenues are primarily driven by product sales from its commercialized travel vaccines (IXIARO, DUKORAL, and IXCHIQ) and sales of third-party products. Additional revenue streams include royalties, partnerships related to vaccine candidates, and collaborations, services, and licensing agreements.